Avanos Medical: Deep Value, Turnaround-Dependent MedTech with Asymmetric Upside Amid Execution Risks
Overview
Avanos Medical, formed from a 2014 Kimberly-Clark healthcare spin-off, is at a pivotal juncture, transitioning from commoditized supplies to a higher-margin, innovation-led model anchored in Specialty Nutrition Systems and Pain Management. The company’s current three-year transformation aims to consolidate its portfolio, localize supply chains, and focus on high-return segments, as evidenced by recent divestitures and acquisitions. Q3 2025 reflected growing demand in SNS but persistent margin issues due to restructuring and external pressures. While management has raised full-year guidance and expresses confidence in the turnaround, investors remain skeptical, pricing the stock at a deep discount. The investment case rests on successful cost reductions, portfolio focus, and restoration of profitability, with material upside contingent on operational execution and stabilization.